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1. Introduction 
The immune system is the body’s main line of defense against invasion by infectious 
organisms, such as bacteria, virus, and fungi. In normal immune systems, an immune 
response does not occur against the self-antigen, and is called self-tolerance. Autoimmune 
diseases occur when body tissues are attacked by the body’s own immune system due to 
loss of tolerance to self-antigens (Dejaco et al., 2006). Under these conditions, body tissues 
are destroyed by antigen-specific cytotoxic T cells or auto-antibodies, and the accompanying 
inflammation can cause functional disability and morbidity. Autoimmune diseases are a 
heterogenous group of diseases with a wide spectrum of symptoms that affect 
approximately 6% of the population (Siatskas et al., 2006). They can be broadly classified as 
organ-specific or systemic depending on the location of the target antigen and clinical 
features (Sakaguchi, 2000). Common examples of systemic autoimmune diseases include 
systemic lupus erythematosus (SLE), rheumatoid arthritis, systemic sclerosis, ankylosing 
spondylitis, and polymyositis; examples of organ-specific autoimmune diseases include type 
1 diabetes, Addison’s disease, Hashimoto thyroiditis, Graves’ disease, Sjögren's syndrome, 
vitiligo, pernicious anemia, glomerulonephritis, myasthenia gravis, Goodpasture’s syndrome, 
autoimmune hemolytic anemia, idiopathic thrombocytopenia purpura, and pulmonary 
fibrosis. The clinical features of autoimmune diseases are very different, but immune-
mediated mechanisms are associated with the generation of an adaptive immune response 
toward the target antigen (Kuby, 1994; Siatskas et al., 2006).   
Conventional treatments, such as corticosteroids, cyclophosphamide, azathioprine, and 
methotrexate, are effective in some patients with autoimmune disease, but they are not 
uniformly effective and are associated with side effects and toxicity (Jantunen et al., 2000; 
Wiesik-Szewczyk et al., 2010).   
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With a better understanding of the pathophysiology of autoimmune diseases, many 
potential novel therapies focusing on cellular or molecular targets have been developed and 
evaluated (Nepom, 2002). This chapter provides a review of the pathophysiology and 
mechanisms underlying the induction of autoimmune diseases and the target sites and 
mechanisms of new therapies, and may help to understand the concept of new therapeutic 
trials that enhance or replace conventional therapies by reducing inflammatory immune 
responses and achieving immunological balance.  
2. Pathophysiology and mechanisms for the induction of autoimmune 
diseases 
The etiology of autoimmune diseases is unknown; however, autoimmune diseases may be 
caused by interplays between genetic factors, inappropriate immune regulation, and 
hormonal and environmental factors. Regarding immune regulation, lymphocytes and 
antigen-presenting cells play important roles in the generation of an effective immune 
response. Immune responses can be broadly divided into humoral and cell-mediated 
immune responses. The term “humoral” is derived from the Latin word “humor,” which 
means body fluid. The humoral immune response involves the interaction of B cells with an 
antigen and subsequent B-cell proliferation and differentiation into antibody-secreting 
plasma cells (Kuby, 1994). Apart from mediating the humoral response via antibody 
production in adaptive immunity, B cells function as antigen-presenting cells and have the 
ability to activate T cells. Furthermore, activated B cells may produce pro-inflammatory 
cytokines, which aggravate local inflammation (Mok MY, 2010). T cells regulate B-cell 
responses, and inflammatory T cells infiltrate target tissues, which can lead to tissue 
damage. Cells expressing major histocompatibility complex (MHC) class II molecules that 
can present peptides to CD4+ T helper (Th) cells are called antigen-presenting cells. Cells 
that constitutively express MHC class II molecules, such as B cells, dendritic cells, 
monocytes, macrophages, thymic dendritic cells, thymic epithelial cells, and human vascular 
endothelial cells, function as antigen-presenting cells (Kuby, 1994). However, inducible 
expression of MHC class II molecules can occur in fibroblasts, glial cells, pancreatic beta 
cells, thyroid epithelial cells, and non-human vascular endothelial cells during an 
inflammatory response (Kuby, 1994). 
In autoimmune disease, immune-mediated mechanisms are associated with the generation 
of an adaptive immune response against the target self-antigen (Siatskas et al., 2006). Many 
self-reactive lymphocytes are deleted during development or maturation, but not all self-
reactive lymphocytes are eliminated. In normal healthy individuals, the activity of mature, 
recirculating self-reactive lymphocytes are regulated by clonal anergy or clonal suppression. 
A breakdown in this regulation results in the activation of self-reactive T- or B-cell clones, 
inducing humoral or cell-mediated responses against the self-antigen.  
As described above, autoimmune diseases do not develop from a single event, but rather 
from many different events. Many mechanisms have been proposed for the induction of 
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autoimmune diseases. Some of the well-known mechanisms include release of sequestered 
antigens, molecular mimicry, inappropriate expression of MHC class II molecules, cytokine 
imbalance, dysfunction of idiotype network regulatory pathways, general regulatory T-cell 
defects, and polyclonal B-cell activation (Kuby, 1994). An overview of the “pathophysiology 
and mechanisms for the induction of autoimmune disease” is presented in Figure 1.  
 
Autoimmune diseases may be caused by interplays between genetic factors, inappropriate immune regulation, and 
hormonal and environmental factors. Immune-mediated mechanisms underlie the development of autoimmune 
diseases. (Ag: antigen, IL-2R: IL-2 receptor, Treg: regulatory T cell, MHC: major histocompatibility complex, APC: 
antigen presenting cell)  
Figure 1. Pathophysiology of autoimmune diseases  
2.1. Sequestered antigens 
Induction of tolerance in self-reactive T cells is thought to occur via exposure of immature 
lymphocytes to self-antigens during development. Thus, sequestered antigens not seen by 
the developing immune system will not induce self-tolerance. However, trauma to tissues 
following an accident or a viral or bacterial infection may release the sequestered self-
antigens into circulation, leading to auto-antibody formation on occasion (Kuby, 1994). 
Multiple sclerosis is the most common autoimmune disorder of the central nervous system 
(CNS). A study on multiple sclerosis revealed that CD8 T cells specific for protein 
sequestered in oligodendrocytes can mount a spontaneous lethal demyelinating attack on 
the CNS without help from other T- or B-cell subsets or signals from the innate immune 
system (Na et al., 2008).  
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2.2. Molecular mimicry 
A variety of bacteria and viruses possess antigenic determinants that are identical or similar 
to host cell components. This molecular mimicry between microbial antigens and host 
proteins can induce the production of activated T cells and antibodies that can cross-react 
with the host’s own cells and lead to autoimmune disease. For example, a recent study using 
bioinformatics tools revealed that some of the identified antigens have been detected in 
established autoimmune diseases associated with mycobacterial infection (Chodisetti et al., 
2012). 
2.3. Inappropriate expression of MHC class II molecules on non-antigen-
presenting cells & MHC molecules and susceptibility to autoimmune diseases 
Inappropriate MHC class II expression was first observed on thyroid cells derived from 
patients with Graves' disease (Hanafusa et al., 1983) and led to the hypothesis that such 
expression can lead to the presentation of thyroid autoantigens to T cells, thereby initiating 
an autoimmune response. Normally, MHC class II molecules are expressed only on antigen-
presenting cells. Healthy beta cells and thyroid acinar cells do not express MHC class II 
molecules. However, pancreatic beta cells in patients with type I diabetes mellitus (Bosi et 
al., 1987) and thyroid acinar cells in patients with Grave’s disease express high levels of 
MHC class II (Hanafusa et al., 1983). This inappropriate expression of MHC class II 
molecules may serve to sensitize Th cells to peptides derived from cells that inappropriately 
express MHC class II molecules, allowing activation of B cells and cytotoxic T (Tc) cells, or 
sensitization of TDTH cells against self-antigen.  
Individuals susceptible to autoimmunity must possess MHC molecules and T-cell receptors 
capable of binding self-antigens. Expression of certain MHC alleles causes susceptibility to 
autoimmune diseases, and the presence of certain domains in T-cell receptors has also been 
linked to many autoimmune diseases (Kuby, 1994). Indeed, several autoimmune diseases, 
including type I diabetes and rheumatoid arthritis, exhibit a strong association and linkage 
with specific sequence polymorphisms in MHC class II molecules (Castaño et al., 1990).  
Trauma or viral infection in an organ may induce localized inflammation. Increased levels 
of interferon (IFN)-γ can induce the expression of MHC class II molecules on a wide variety 
of non-antigen-presenting cells, thereby causing autoimmune disease (Todd et al., 1985). 
Further, the combination of IFN-γ with tumor necrosis factor (TNF)-α or interleukin (IL)-1β 
increases the expression of class I and II antigens in human thyroid follicular cells, 
compared with the effect of IFN-γ alone (Migita et al., 1990).  
2.4. Cytokine imbalance 
CD4+ Th cells can be subdivided into Th1, Th2, Th17, and regulatory T cells, on the basis of 
the cytokines they produce and the functions they perform (Cooke, 2006). Th1-type cytokines 
tend to produce the pro-inflammatory responses responsible for killing intracellular parasites 
such as viruses and certain bacteria, perpetuating autoimmune responses, and causing cell-
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mediated allergies. Preferential activation of Th1 cells plays a central role in the pathogenesis 
of many autoimmune diseases, including type 1 diabetes mellitus, multiple sclerosis, and 
rheumatoid arthritis (Emamaullee et al., 2009). The primary cytokines secreted from Th1 cells 
include IL-2, IFN-γ, and TNF-β. Overproduction of these cytokines from activated Th1 cells 
can induce excessive B-cell activation and autoantibody production (Kuby, 1994). In contrast, 
induction of Th2 populations results in a dominant protective effect against autoimmunity 
(Suarez-Pinzon and Rabinovitch, 2001; Sia, 2005). Th2-type cytokines include IL-4, IL-5, and 
IL-13, which are associated with the promotion of allergic responses, and IL-10, which 
produces anti-inflammatory responses. In fact, autoimmune diseases can be ameliorated by a 
reduced Th1 response or a shift toward Th2 responses in some cases, but there are exceptions.  
Th17 occurs at the sites of interaction between the internal and external environments of the 
body. Important cytokines of Th17 include IL-17, IL-12, and IL-23. IL-17 is a potent pro-
inflammatory cytokine that elicits the production of other inflammatory cytokines and 
chemokines such as TNF-α, IL-1ß, IL-6, IL-8, GM-CSF, and MCP-1 by endothelial cells, 
epithelial cells, and other cell types such as fibroblasts, keratinocytes, synoviocytes, and 
macrophages (Waite and Skokos, 2012). Thus, IL-17 can amplify ongoing inflammation. IL-
17 levels were elevated in many inflammatory autoimmune diseases, including systemic 
sclerosis, psoriasis, and rheumatoid arthritis (Chabaud et al., 1999). Furthermore, several 
autoimmune conditions that were previously assumed to be mediated by Th1 have now 
been shown to involve Th17 cells (Cooke, 2006). 
2.5. General regulatory T cell defects 
The CD4+ regulatory T cell subsets include IL-10–producing T regulatory cell type 1 (Tr1), 
transforming growth factor (TGF)-β–secreting T helper cell type 3 (Th3), and a 
subpopulation of naturally occurring regulatory T cells that express high levels of CD25 and 
the forkhead box P3 (FoxP3) (Dejaco et al., 2005). Lack of regulatory T cells that express CD4, 
CD25, and FoxP3 induces severe autoimmunity in both mice and humans (Buckner, 2010). 
General regulatory T-cell defects cause hyperactivity of both B and T cells. Thus, restoration 
of regulatory T cells can reverse autoimmunity. Studies on the functional assays revealed 
that regulatory T cells play a crucial role in the modulation of local immune responses (de 
kleer et al., 2004). Altered generation of regulatory T cells and insufficient suppression of 
inflammation are considered pivotal for the initiation and perpetuation of autoimmune 
diseases because imbalance between pro-inflammatory and regulatory T cells can lead to the 
breakdown of self-tolerance (Dejaco et al., 2005). In fact, reduced levels of circulating 
CD4+CD25high T cells were observed in patients with juvenile idiopathic arthritis (de kleer 
et al., 2004). Further, lower levels of circulating CD4+CD25high T cells also correlate with 
higher disease activity or poorer prognosis (de kleer et al., 2004). 
2.6. Dysfunction of the idiotype network regulatory pathways  
Production of anti-idiotype antibodies against self-proteins can contribute to autoimmune 
disease. For example, in Grave’s disease, antibodies produced against the thyroid-
stimulating hormone (TSH) receptor bind to the receptor and inappropriately stimulate the 
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thyroid. Antibodies against the “TSH-specific antibody” (anti-idiotype antibody) can 
stimulate the TSH receptor. Anti-idiotype antibodies were found in patients with 
myasthenia gravis (Dwyer et al., 1983) and a patient with Grave’s disease (Kuby, 1994).  
2.7. Polyclonal B-cell activation 
Many bacteria and viruses, such as gram-negative bacteria, cytomegalovirus, and Epstein-
Barr virus, can induce nonspecific polyclonal B-cell activation without the help of Th cells. 
Lipopolysaccharide from gram-negative bacteria is sufficient to induce autoimmune disease 
in an immunologically normal host, suggesting that polyclonal B-cell activation plays a 
central role in the pathogenesis of systemic autoimmune diseases (Granholm, 1992). Indeed, 
autoimmune diseases can be arrested by suppressing excessive polyclonal B-cell activation, 
and autoimmune diseases can be exacerbated by enhancing polyclonal B-cell activation.   
3. Strategies to influence specific immune cells and molecules such as co-
stimulatory molecules, cytokines, and chemokines 
The immunity-related strategy for treating autoimmune diseases is to arrest ongoing 
inflammatory responses, prevent the adaptive memory response, and achieve antigen-
specific immunomodulation (Nepom GT, 2002). During the past several decades, strategies 
using agents that influence cytokines, hyperactivity of B cells, and B cell-T cell interaction 
have proven to be effective and safe therapies for autoimmune disease (Lacki JK, 2000). 
Overviews of the “Generation of adaptive immune response against the target self-antigen” 
and “Target sites of new therapies influencing specific immune cells, molecules, cytokines, 
and chemokines” are presented in Figure 2.  
3.1. B-cell-based therapy  
Strategies targeting B cells include B-cell depletion therapies, anti-cytokine therapies, B-cell 
tolerogens, and inhibition of co-stimulatory molecules (Mok MY, 2010).  
Potential targets for B-cell therapy include cell surface molecules and co-stimulatory 
molecules, such as CD20, CD22, B220, MHC class II molecules, CD35 (CR1), CD21 (CR2), 
CD32 (FcγRII), CD80 (B7-1), CD86 (B7-2), and CD40.  
3.1.1. B-cell depletion therapies  
CD20 is a B-cell-restricted surface molecule and an activated-glycosylated phosphoprotein 
that is expressed from pre-B to memory B cells (Mok MY, 2010). Anti-CD20 antibody (Ab) 
treatment results in B-cell depletion via antibody-dependent cell-mediated cytotoxicity, 
complement-mediated lysis, and stimulation of apoptosis (Pescovitz, 2006). Anti-CD20 Ab 
treatment was administered for B-cell depletion in human SLE (Anolik et al., 2007, Smith et 
al., 2006), autoimmune hemolytic anemia (Quartier et al., 2001; Perrotta et al., 2002), and 
rheumatoid arthritis (Furst et al., 2007). Clinical trials for SLE proved that anti-CD20 Ab 
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treatment has beneficial effects only on B-cell-driven SLE because beneficial effects were 
seen only in the African American and Hispanic subgroups, which are refractory to 
standard treatment and are more B-cell dependent (Isenberg et al., 2008). The main 
complication relating to anti-CD20 Ab treatment is an increased rate of serious infection, 
which terminated the clinical trials (Hutas et al., 2008).  
  
In autoimmune diseases, an adaptive immune response is mounted against the target self-antigen. The target sites of 
the new therapies are shown.  
3.1.1 B-cell depletion therapies  
3.1.2 B-cell-related anti-cytokine therapies 
3.1.3 Therapy using B-cell tolerogens  
3.2.1 Therapies targeting T-cell surface molecules 
3.2.2 Therapies targeting T-cell pathways related to trafficking and co-stimulation  
3.2.3 T-cell vaccination 
3.2.4 Therapies targeting MHC molecules or antigen-presenting cells in the first signal  
3.2.5 Therapies targeting antigens in the first signal  
3.2.6 Therapy using T-cell tolerogens 
3.3 Therapy targeting B cell-T cell interaction (inhibition of co-stimulatory molecules) 
3.4 Anti-cytokine therapy (prevention of ongoing inflammatory responses)  
(APC: antigen presenting cell, Tc: cytotoxic T cell, TCR: T cell receptor, MHC: major histocompatibility complex, Ag: 
antigen, LFA: lymphocyte function-associated antigen, CD: cluster of differentiation, VLA: very late antigen, ICAM: 
intercellular adhesion molecule, TACI: transmembrane activator and calcium modulator and cyclophilin ligand interactor, 
BCMA: B-cell maturation antigen, BAFF-R: B-cell-activating factor receptor, BLys: B-lymphocyte stimulator, IFN: 
interferon, IL: interleukin, GM-CSF: granulocyte-macrophage colony-stimulating factor, TNF: tumor necrosis factor) 
Figure 2. Target sites of new therapies influencing specific immune cells, molecules, cytokines, and 
chemokines 
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CD22 is a B-cell surface glycoprotein and a specific adhesion molecule that regulates antigen 
receptor signaling, B-cell activation, and interaction with T cells (Tedder et al., 1997). Anti-
CD22 Ab treatment was tested in 14 SLE patients in an open-labeled study. No reduction in 
ANA or anti-dsDNA antibodies (Abs) was observed, but induction of B-cell modulation and 
evidence of clinical improvement were seen (Dörner et al., 2006; Carnahan et al., 2007). The 
action of anti-CD22 Abs is achieved by antibody-dependent cell cytotoxicity and induction 
of signal transduction via downmodulation of B-cell receptor signaling (Carnahan et al., 
2007).  
3.1.2. B-cell-related anti-cytokine therapies 
The B-lymphocyte stimulator (BLys), also called B-cell-activating factor (BAFF), is important 
in B-cell immunity (Moore et al., 1999). BLys is a TNF family ligand expressed on the cells of 
myeloid origin, such as monocytes, macrophages, and dendritic cells, and can bind to 3 
membrane receptors on B cells, including transmembrane activator and calcium modulator 
and cyclophilin ligand interactor (TACI), B-cell maturation antigen (BCMA), and BAFF 
receptor (BAFF-R). Anti-BLys Ab treatment decreased CD20+ B cells, reduced anti-dsDNA 
Abs and disease flares, and stabilized SLE, in particular, in serologically active SLE patients 
(Wallace et al., 2009; Wiglesworth et al., 2010).   
Treatment with BAFF-R linked to the Fc domain of human IgG1 ameliorated murine SLE, 
judging from the decrease in anti-dsDNA Abs and proteinuria and the improvement in 
glomerular lesions (Kayagaki et al., 2002).  
TACI-IgG can inhibit BLys and a proliferation-inducing ligand (APRIL), and TACI-IgG 
treatment decreased proteinuria and prolonged survival in murine lupus (Gross et al., 2000).  
3.1.3. Therapy using B-cell tolerogens  
Abetimus sodium is a synthetic compound of 4 deoxynucleotide sequences bound to a 
triethylene glycol backbone that can bind to anti-dsDNA Abs and crosslink B-cell receptors 
that recognize dsDNA. Thus, treatment with abetimus sodium induces deletion or anergy of 
anti-dsDNA Ab-producing B cells. Abetimus sodium was used as a B-cell tolerogen in SLE 
patients with lupus nephritis and it exhibited potential efficacy in some SLE patients with 
elevated anti-dsDNA Abs. However, a phase IV trial was prematurely terminated because 
of lack of clinical efficacy (Wiesik-Szewczyk et al., 2010).  
3.2. T-cell-based therapy and therapies targeting the first signal  
3.2.1. Therapies targeting T-cell surface molecules 
Monoclonal antibodies to T-cell surface molecules (CD3, CD4, and CD52) have been effectively 
used in clinical efficacy trials for autoimmune diseases, but all of them were associated with 
transient depression of circulating T cells. For example, treatment of New Zealand black × 
New Zealand white (NZB/W) F1 and the autoimmune disease-prone non-obese diabetic 
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(NOD) mice with anti-CD4 Abs blocked nonspecific overall immune responses (Phillips et al., 
2000). A clinical trial using anti-CD52 Abs revealed that profound lymphopenia, with recovery 
B cells and CD8+ cells and longer lasting CD4 cytopenia can occur (Willis et al., 2001). A 
monoclonal antibody directed against the α subunit of the high-affinity IL-2 receptor can more 
specifically block autoreactive Th cells in autoimmunity, because only activated Th cells 
express the high affinity IL-2R α subunit, CD25. Therapy with a monoclonal antibody to the 
IL-2 receptor CD25 led to downregulation of the receptor without depleting T cells. Egan et al. 
(2001) and Haufs and Haneke’s (2001) studies showed the efficacy of anti-CD25 Abs in 
epidermolysis bullosa acquista. In a study on multiple sclerosis, maintenance therapy with 
anti-CD25 Abs reduced the frequency of CD4+CD25+ regulatory T cells, but inflammatory 
activity in multiple sclerosis was substantially reduced with anti-CD25 Ab treatment despite 
reduction of circulating regulatory T cells (Oh et al., 2009).  
3.2.2. Therapies targeting T-cell pathways related to trafficking and co-stimulation  
Lymphocyte function-associated antigen-3 (LFA-3, CD58) is a cell-bound immunoglobulin 
superfamily receptor with only one known ligand, namely, CD2 (Springer et al., 1987). LFA-
3 is widely expressed on human hematopoietic and non-hematopoietic tissues, leukocytes, 
erythrocytes, endothelial and epithelial cells, and fibroblasts. The engagement of LFA-3 with 
CD2 optimizes immune recognition and initiates T-cell expansion and activation. These 
contact activities can occur between helper T cells and antigen-presenting cells and cytolytic 
effectors and target cells. The soluble LFA3/IgG1 fusion protein binds CD2 on T cells and Fc 
receptor on natural killer cells, macrophages, neutrophils, and mast cells. Thus, the soluble 
LFA3/IgG1 fusion protein can inhibit immune recognition as well as T-cell expansion and 
activation. 
LFA-1 is found on all T-cells and also on B-cells, macrophages and neutrophils and is 
involved in recruitment to the site of infection. It binds to ICAM-1 on antigen-presenting 
cells and functions as an adhesion molecule. Anti-LFA1 Ab treatment elicited an 
improvement in psoriasis (Papp et al., 2001; Tutrone et al., 2001). 
Very late antigen-4 (VLA-4) is an integrin dimer composed of CD49d (alpha) and CD29 
(beta). VCAM-1 (integrin receptor) binds to VLA-4 normally expressed on leukocyte plasma 
membrane, but does not adhere to the appropriate ligands until the leukocytes are activated 
by chemotactic agents or other stimuli. Treatment with the anti-α4 integrin Abs (VLA-4 
Abs), which targets T-cell trafficking pathways, also showed clinical benefit in Crohn’s 
disease and multiple sclerosis (Tubridy et al., 1999; Gordon et al., 2001).  
3.2.3. T-cell vaccination 
Cross-linked T cells apparently elicit regulatory T cells specific to T-cell receptor variable 
region determinants of the autoimmune clones, and it has been shown that a synthetic T-cell 
receptor variable region peptide can function as a vaccine and an effective therapy (Kuby, 
1994). For example, treatment with the IR501 therapeutic vaccine, which consists of a 
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combination of 3 peptides derived from T cell receptors (Vβ3, Vβ14, and Vβ17) in Freund’s 
incomplete adjuvant, was safe and well tolerated, and showed clinical improvement in 
rheumatoid arthritis patients (Moreland et al., 1998).  
3.2.4. Therapies targeting MHC molecules or antigen-presenting cells in the first signal  
Expression of certain MHC alleles causes susceptibility to autoimmune diseases. Thus, 
selective inhibition of MHC molecules, which are associated with autoimmunity, by using 
monoclonal antibodies can delay and ameliorate autoimmune diseases (Kuby, 1994). For 
example, treatment with anti-MHC class II monoclonal Abs (monoclonal Abs to the murine 
I-E equivalent) prevented thyroidal and pancreatic autoimmunity in BioBreeding/Worcester 
(BB/W) rats (Boitard et al., 1985). Treatment of anti-I-A monoclonal Abs ameliorated many 
autoimmune diseases in animal models including lupus nephritis (NZB/W F1) (Adelman et 
al., 1983), experimental autoimmune uveoretinitis (Rao et al., 1989), and experimental 
autoimmune myasthenia gravis (Waldor et al., 1983). Engineered antigen-presenting cells 
have also been used for immunomodulation and tolerance induction. For example, FasL-
expressing antigen-presenting cells that specifically interact with Fas molecules on the 
surface of lymphocytes induce lymphocyte apoptosis (Zhang et al., 1999).  
3.2.5. Therapies targeting antigens in the first signal  
Oral presentation of T-cell-dependent antigens can lead to immunity or tolerance depending 
on the form of the antigen, dose, and number of feedings (Tomasi, 1980, Titus and Chiller, 
1981). Thus, parenteral administration of antigens or antigen analogs was evaluated as 
immunotherapy for autoimmune diseases. Myelin basic protein (MBP)-specific T cells and 
symptoms of multiple sclerosis were reduced in myelin-fed, HLA-DR2-negative patients 
(Weiner et al., 1993). Mice fed MBP do not develop experimental autoimmune 
encephalomyelitis (experimental allergic encephalomyelitis, EAE) following subsequent 
injection of MBP (Kuby, 1994). Type II collagen-induced arthritis is an animal model of 
polyarthritis induced in susceptible mice and rats by immunization with type II collagen, a 
major component of cartilage. Intragastric administration of soluble type II collagen, prior to 
immunization with type II collagen in adjuvant, suppressed the incidence of collagen-
induced arthritis (Nagler-Anderson C, 1986; Trentham et al., 1993).  
A synthetic polypeptide comprising a random mixture of alanine, glutamate, lysine, and 
tyrosine, which can bind MHC and elicit T-cell recognition, acts as an altered antigen ligand. 
Treatment using this synthetic polypeptide showed beneficial effects on multiple sclerosis 
(Fusco C, 2001).  
3.2.6. Therapy using T-cell tolerogens 
hCDR1 (TV-4710, Edratide) is a peptide derived from the immunoglobulin Vh region of 
human anti-dsDNA Abs. Treatment with hCDR1 as a T-cell tolerogen induced regulatory T 
cells and reduced proteinuria and immune complexes in the kidneys of SLE patients. In this 
 
New Therapeutic Challenges in Autoimmune Diseases 263 
study on gene expression in peripheral blood mononuclear cells from SLE patients, 
treatment using hCDR1 increased in vivo gene expression of TGF-, FoxP3 and the anti 
apoptotic molecule Bcl-xL, but significantly decreased the gene expression of IL-1, TNF-, 
IFN-, IL-10, BLyS, caspase-3, and caspase-8. hCDR1 treatment also markedly decreased 
disease activity (Sthoeger et al., 2009).   
3.3. Therapy targeting B cell-T cell interaction (inhibition of co-stimulatory 
molecules) 
T-cell activation requires 2 signals and cytokines. The first signal is mediated via binding of 
the T-cell receptor to the antigen presented with MHC molecules on antigen-presenting 
cells. However, the first signal alone is not sufficient; a second co-stimulatory signal is also 
required. Thus, co-stimulation is important not only for normal immunity, but also for the 
pathogenesis of autoimmunity. Therapies targeting the 2 main co-stimulatory pathways B7-
CD28 and CD40-CD40L have been evaluated. Anti-CD40L Ab treatment reduced 
inflammation, vasculitis, and fibrosis in the kidney and increased survival in a murine lupus 
model, the SNF1 mouse (Kalled et al, 1998). Anti-CD40L Ab treatment also elicited clinical 
improvements such as decrease in anti-dsDNA Abs and hematuria and increase in C3 in 
some SLE patients. However, thromboembolism complications prevented continuation of 
the phase II study (Mok et al., 2010). CTLA4Ig is a fusion protein comprising the 
extracellular domain of CTLA4 and the constant region of immunoglobulin. CTLA4Ig 
competes with CD28 for binding to B7 thereby inhibiting the B7-CD28 co-stimulatory signal. 
CTLA4Ig treatment elicited improvements in murine SLE, judging from the decrease in 
proteinuria and increase in survival (Finck et al., 1994). CTLA4Ig gene therapy also had 
beneficial effects on canine SLE (Choi et al., 2005) and canine experimental autoimmune 
thyroiditis (Choi et al., 2008). A phase III clinical trial using CTLA4Ig in human SLE is 
currently underway (Mok, 2010).  
3.4. Anti-cytokine therapy (prevention of ongoing inflammatory responses) 
Inhibitors of inflammatory cytokines, such as a decoy receptor for inflammatory cytokines, 
have produced promising results in animal models of autoimmune diseases.  
TNF-α is an inflammatory cytokine produced by various cells such as monocytes, 
macrophages, T cells, and B cells. TNF-α stimulates the production of other cytokines such 
as IL-1, IL-6, IL-8, and GM-CSF. To prevent ongoing inflammatory responses, TNF-blocking 
agents were administered in patients with psoriasis, rheumatoid arthritis, or Crohn’s 
disease, and were shown to be efficacious (Chaudhari et al., 2001; Keating and Perry, 2002). 
However, ANA and anti-dsDNA Abs were observed in some rheumatoid arthritis or 
Crohn’s disease patients treated with TNF-blocking agents (De Bandt et al., 2005; Mohan et 
al., 2002). TNF-blocking agents were ineffective in multiple sclerosis (Skurkovish et al., 
2001). The diseases frequently recurred after discontinuation of TNF-blocking agent therapy. 
Further, Furst et al. recommend that caution should be exercised when using TNF-blocking 
agents. According to them, TNF-blocking agents should not be initiated or should be 
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discontinued when serious infections occur (Furst et al., 2001). Instances of demyelinating-
like disorders, pancytopenia, and aplastic anemia have been reported in patients receiving 
TNF blockers (Furst et al., 2002). A recent study reported the association of TNF inhibitor 
treatment with the risk of elevated liver enzymes, such as ALT and AST in patients with 
rheumatoid arthritis (Sokolove et al., 2010). A TNF-blocking agent in conjunction with 
baseline immunosuppressive therapy significantly decreased proteinuria and attenuated 
arthritis in SLE patients (Aringer et al., 2004). A trial evaluating a TNF-blocking agent in 
membranous nephritis is currently underway (Wiesik-Szewczyk et al., 2010).  
IFN-γ is also a pleiotropic cytokine that is a key effector in the pathogenesis of various 
autoimmune diseases. Intramuscular injections of plasmids with cDNA encoding IFN-γR/Fc 
can retard lupus development and progression in MRL-Fas(lpr) mice. The therapy 
significantly reduced serum levels of IFN- and autoantibodies, lymphoid hyperplasia, and 
glomerulonephritis, and increased survival (Lawson et al., 2000).  
IL-12 is an inflammatory cytokine that plays a pivotal role in the development of 
autoimmune diseases, such as those in the NOD mouse. Gene transfer using a modified 
form of IL-12 into pancreatic beta islet cells decreased the activity of natural IL-12 and 
prevented the onset of diabetes in NOD mice (Yasuda et al., 1998).  
IL-6 is produced by monocytes, T cells, B cells, and mesangial cells. IL-6 stimulates B-cell 
maturation and immunoglobulin production. Combined with other cytokines, IL-6 also 
induces neutrophil activation, T-cell proliferation, and differentiation to cytotoxic T cells 
(Tackey et al., 2004). A monoclonal antibody against the IL-6 receptor α chain inhibits the 
binding of IL-6 to its receptor. Some SLE patients treated with this monoclonal antibody 
exhibited a significant decrease in acute phase reactant, activated B cells and memory B cells 
(Lacki et al., 1997). Furthermore, IL-6 receptor Ab treatment has been shown to be rapidly 
efficacious in patients with severe rheumatoid arthritis (Jones and Ding, 2010). However, 
complications relating to abnormalities in CBC and serum chemistry, such as neutropenia, 
increased concentrations of liver enzymes, cholesterol, and triglycerides, were observed in 
rheumatoid arthritis patients treated with anti-IL-6 receptor α chain monoclonal Abs (Iebba et 
al., 2012). The US Food and Drug Administration (FDA) approved the intravenous infusion 
of a monoclonal antibody against the IL-6 receptor α chain (tocilizumab) in adult patients 
with severely active rheumatoid arthritis who had an inadequate response to TNF antagonist 
therapies (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm251572.htm).  
An IL-1-blocking agent (IL-1 receptor antagonist) has been approved for use in rheumatoid 
arthritis. However, its use also increased the incidence of serious bacterial infections. A 
recent meta-analysis study revealed that the IL-1 receptor antagonist is less effective than 
TNF-α inhibitors for the treatment of rheumatoid arthritis (Furst et al., 2010).  
As described in the previous section, IL-17 plays a central role in early inflammation and 
eosinophil recruitment. Therapeutic agents that target Th17, such as anti-IL-17 Ab and IL-25, 
showed promising results in animal models of autoimmunity. Anti-IL-17 Ab treatment 
reduced Th17 population, and prevented inflammation and bone erosion in experimental 
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rheumatoid arthritis by decreasing RANKL and IL-1 (Koenders et al., 2005). Multiple 
treatments with anti-IL-17 Abs dramatically reduced inflammatory lesions and neurological 
signs in experimental autoimmune encephalomyelitis (Hofsttter et al., 2005). IL-25 has 
shown to inhibit Th17 cells and promote the development of Th2 responses (Angkasekwinai 
et al., 2007). Further, a recent study showed that IL-25 regulates Th17 function in 
autoimmune inflammation (Kleinschek et al., 2007). Treatment with anti-IL-17 Abs or IL-25 
prevented progression to diabetes in pre-diabetic NOD mice, reduced islet inflammation, 
and prevented glutamic acid decarboxylase (GAD) 65 autoantibody formation (Emamaulle 
et al., 2009). Clinical trials of anti-IL-17 Abs in autoimmune diseases, including rheumatoid 
arthritis, psoriasis, and Crohn’s disease, are currently underway (www. clinicaltrials.gov). A 
recent study revealed that a small molecule, halofuginone (HF), selectively inhibits mouse 
and human Th17 differentiation by activating a cytoprotective signaling pathway, the amino 
acid starvation response (AAR) (Sundrud et al., 2009). Further, this study showed that HF 
prevented experimental autoimmune encephalomyelitis by inducing AAR. 
3.5. Protective cytokine gene therapy and induction or replacement of regulatory 
T cells  
Studies on cytokine gene therapy using viral or nonviral vectors have been conducted in 
animal models of autoimmune diseases, including type 1 diabetes mellitus, EAE, SLE, 
colitis, thyroiditis, and various forms of arthritis. The purpose of this therapy is to modify 
the inappropriate inflammatory immune responses in autoimmune disease. Genes encoding 
TGF-β, IL-4, and IL-10 are most frequently protective. For example, IL-10 gene therapy 
using replication-deficient adenovirus administered directly into the CNS prevented disease 
progression in murine EAE, whereas systemic administration of IL-10 gene therapy using 
adenovirus had little effect on EAE (Cua et al., 2001). Intramuscular injection of IL-10 gene 
therapy prevented diabetes induced by streptozotocin injections in mice (Zhang et al., 2003). 
IL-4 gene therapy using adenovirus administered directly into limb joints decreased 
inflammation and improved pathology in a rat model of adjuvant-induced arthritis (Woods 
et al., 2001). Monthly intramuscular injections of cDNA expression vectors encoding TGF-β1 
significantly elevated the serum levels of TGF-β, prolonged survival, and elicited beneficial 
effects in the MRL/lpr murine model of SLE (Raz et al., 1995). Systemic TGF-β1 gene therapy 
using an adenoviral system followed by syngeneic islet transplantation induced Foxp3+ 
regulatory cells, restored self-tolerance, and facilitated the survival of islet grafts and 
recovery of -cell function in overtly diabetic NOD mice (Luo et al., 2005). Chen et al. 
reported that TGF--induced Foxp3 gene expression has the ability to convert CD4+CD25- 
naive T cells to regulatory T cells with potent immunosuppressive potential (Chen et al., 
2003).  
The transfer of CD4+CD25+ regulatory T cells conferred significant protection against 
clinical EAE in a mouse model of multiple sclerosis (Kohm et al, 2002). Treatment with in 
vitro-expanded antigen-specific regulatory T cells from autoimmune-prone NOD mice also 
reversed diabetes after disease onset (Tang et al., 2004). Further, antigen-specific T cells 
transduced with FoxP3 using a retroviral system prevented diabetes in NOD mice (Jaeckel 
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et al., 2005). These studies suggested that regulatory T cells act as main regulators of the 
immune system and provide a novel approach to cellular immunotherapy for autoimmune 
diseases.  
4. Stem cell therapy for autoimmune diseases  
4.1. Hematopoietic stem cell transplantation  
Non-disease prone animals that received bone marrow derived from diseased hosts 
developed autoimmune diseases (Berisso et al., 1999) and vice versa. This suggested that the 
hematopoietic compartment plays an important role in autoimmune disease susceptibility, 
and transplantation of autologous or allogeneic non-autoimmune disease-prone 
hematopoietic cells can attenuate autoimmune disease. Autologous, syngeneic, and 
allogeneic bone marrow (or hematopoietic stem cell) transplantations have been performed 
in animal models of human autoimmune diseases, including EAE (Burt et al., 1998; Karussis 
et al., 1993), experimental autoimmune myasthenia gravis (Pestronk et al., 1983), adjuvant-
induced arthritis (van Bekkum, 1989), collagen-induced arthritis (Kamiya et al., 1993), type 1 
diabetes (NOD mice) (Beilhack et al., 2003), and SLE-like autoimmune diseases (MLR/lpr 
mice and NZB/W F1 mice) (Ikehara, 2001; Smith-Berdan et al., 2007). The results from these 
animal studies suggested that myelo-ablative therapy supported by stem cell 
transplantation can result in remission of disease or induction of immune tolerance. The 
bone marrow was the initial source of hematopoietic stem cells, but peripheral blood is 
currently used following mobilization procedures comprising a combination of 
cyclophosphamide and G-CSF (Saccardi and Gualandi, 2008).  
The therapeutic concept of hematopoietic stem cell transplantation is to reset the immune 
system. Thus, patients receive aggressive immunosuppression to eliminate autoreactive 
lymphocytes (to ablate the immune system), and disease remission occurs via de novo 
regeneration of immunocytes from hematopoietic stem cells. Two mechanisms have been 
proposed. The first is re-education of the defective immune system by restoring diverse 
antigen-specific clones via reactivation of the thymic output and regenerating the adaptive 
immune system that had became apparently tolerant to self-antigens (Abrahamsson and 
Muraro, 2008). The second mechanism is reconstitution of the regulatory T-cell pool after 
stem cell transplantation. Regulatory T cells are important for preventing autoreactivity and 
control autoimmunity throughout life (Zhang et al., 2009). The rationale of allogeneic stem 
cell transplantation is substitution of the faulty immune system with a normal healthy one. 
However, the burden of higher mortality and morbidity due to graft versus host disease 
prevents its use in autoimmune disease except immune cytopenia. Allogeneic 
transplantation may be an option for selective patients who are not suitable for or have 
previously undergone autologous hematopoietic stem cell transplantation. 
Autologous BM transplantation for autoimmune diseases has no risk of graft-versus-host 
disease, but relapses are common (Chan et al., 2008). For example, a case report on 
autologous hematopoietic stem cell transplantation in non-Hodgkin’s lymphoma concurrent 
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with Crohn’s disease discussed that autologous hematopoietic stem cell transplantation will 
not provide a long-term cure for Crohn’s disease (Anumakonda et al., 2007). In this case 
report, the authors postulated that autologous hematopoietic stem transplantation led to 
ablation of activated T cells for a prolonged period (8 years), but the genetic predisposition 
(positive family history) concurrent with other environmental factors such as smoking 
subsequently led to disease relapse. In case of genetically determined autoimmunity, an 
allogeneic source of stem cells is necessary to prevent a relapse of autoimmunity (Jorgensen 
et al., 2003). Patients with a refractory autoimmune disease that does not respond to current 
conventional treatments may be considered for stem cell transplantation. Pilot studies were 
conducted in systemic sclerosis (Tyndall et al., 1997; Martini et al., 1999), rheumatoid 
arthritis (Durez et al., 1998), SLE (Burt et al., 1997; Marmont et al., 1997), multiple sclerosis 
(Burt et al., 1998), and hematological autoimmune diseases, such as idiopathic 
thrombocytopenia (Lim et al., 1997), autoimmune hemolytic anemia, and Evans syndrome. 
Some promising results have been reported from phase I/II trial studies, and phase III 
randomized controlled trials are currently underway (http://clinicaltrials.gov/). Over one-
third of patients achieved durable remission and transplant-related mortality reached 12% 
in the initial “European group for Blood and Marrow Transplants” (EBMT) registry, which 
decreased to around 5% in a recent EBMT study (Farge et al., 2010). Susceptibility to 
bacterial, viral, and fungal infections increases until the immune system is reconstituted, 
which makes the hematopoietic stem cell transplantation a high-risk therapy. The major 
complications of hematopoietic stem cell transplantation include septicemia, pneumonia, 
increased risk of late infection, infertility, and secondary malignancies, such as acute 
leukemia and myelodysplastic syndrome.  
4.2. Mesenchymal stem cell transplantation  
Mesenchymal stem cells (MSCs) are multipotent adult stem cells that are the progenitors of 
multiple mesenchymal lineages (Pittenger et al., 1999). The therapeutic mechanisms of MSC 
transplantation include capacity for differentiation and transdifferentiation, paracrine 
effects, immunomodulatory properties, and capacity for directional migration. MSCs have 
immunoprivileges. MSCs can escape the immune system because they lack MHC class II or 
co-stimulatory molecules, such as B7, CD40, and CD40L, which leads to poor recognition by 
T cells (Deans et al., 2000). Moreover, a number of in vitro studies have revealed that MSCs 
exert immunosuppressive and immunomodulatory effects on MHC-mismatched 
lymphocyte proliferation by inhibiting naïve, memory, and activated T cells, B cells, NK 
cells, and dendritic cells (Bartholomew et al., 2002; Di Nicola et al., 2002). MSCs release 
paracrine factors, including trophic, chemoattractant, and immunomodulatory factors. 
Immunomodulatory factors secreted by human MSCs include TGF-β, HGF, PGE2, 
hemoxygenase-1, human leukocyte antigen-G5, and IL-10 (Wang et al., 2011). They are 
constitutively produced by MSCs or after cross-talk with target cells, and their production is 
also enhanced by cytokines secreted by target cells after cross-talk (Wang et al., 2011). MSCs 
exhibit immunomodulatory properties by direct cell-to-cell contact and/or release of soluble 
immunosuppressive factors (Uccelli et al., 2008). MSCs possess the capacity to home to 
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mesenchymal tissues, and injured sites in particular, which may also contribute to 
autoimmune disease treatment. According to the study by Ponte et al., human bone marrow 
MSCs (BMMSCs) express the following tyrosine kinase receptors: platelet-derived growth 
factor receptor (PDGF-R)α; PDGF-Rβ; and insulin-like growth factor receptor (IGF-R). MSCs 
also express ‘regulated upon activation, normal T-cell expressed, and secreted (RANTES) 
and macrophage-derived chemokine (MDC) receptors (CCR2, CCR3, and CCR4)’ and 
‘stromal-derived factor (SDF)-1 receptor (CXCR4)’ (Ponte et al., 2007). 
Survival results from an animal study comparing whole bone marrow cell transplantation 
with adherent cell (MSC)-removed bone marrow cell transplantation revealed that MSCs 
play a critical role in the treatment of lupus in the MLR/lpr mouse model. All mice treated 
with whole bone marrow cells survived more than 1 year, but 75% of mice treated with 
MSC-removed bone marrow cells died within 3 months (Ishida et al., 1994). Total bone 
marrow transplants consist of both hematopoietic stem cells and stromal cells, and MSCs 
play a pivotal role in tolerance induction (Jorgensen et al., 2003).  
Initially, MSCs were isolated from the bone marrow and later from various other tissues, 
including placenta, muscle, cartilage, and fat (da Silva Meirelles L et al., 2006).  
Recently, syngeneic, allogeneic, and xenogeneic MSC transplantations have been performed 
for autoimmune diseases in various animal models, including autoimmune encephalomyelitis 
(Zappia et al., 2005; Rafei et al., 2009; Constantin et al., 2009), type I diabetes (Fiorina et al., 
2009), inflammatory bowel disease (Gonzalez-Rey et al., 2009), rheumatoid arthritis (González 
et al., 2009), and SLE (Zhou et al., 2008; Sun et al., 2009; Choi et al., 2012). These studies yielded 
some promising results. For example, long-term serial administration of human adipose 
tissue-derived MSCs increased survival rates, improved serologic, immunologic, and 
histologic abnormalities, and decreased the incidence of severe proteinuria in NZB/W F1 mice, 
a murine SLE model. The levels of IL-4 and IL-10 in the serum and the proportion of 
CD4+FoxP3+ regulatory T cells in the spleen were increased in NZB/W F1 mice treated with 
MSCs, compared to control NZB/W F1 mice treated with saline (Choi et al., 2012). Clinical 
studies using allogeneic MSC transplantation in refractory SLE patients revealed 
improvements in serologic parameters and renal function (Sun et al., 2009; Liang J et al., 2010). 
Furthermore, pilot studies using autologous BMMSC transplantation in patients with 
refractory Crohn’s disease also yielded promising results (Duijvestein et al., 2010; Ciccocioppo 
R et al., 2011). Clinical trials using MSCs for diabetes and lupus nephritis are underway 
(http://clinicaltrials.gov/).  
4.3. Genetically modified stem cell therapy (Stem cell-based gene therapy) 
Gene therapy-assisted stem cell transplantation has become one of the most attractive 
therapies in clinical immunology (Marmont, 2011). The use of genetically selected or 
genetically engineered cell types can further control the possibility of disease progression or 
relapse. Hematopoietic stem cells engineered to express autoantigens in resting antigen-
presenting cells can be used to prevent autoimmune diseases. For example, syngeneic 
transplantation of hematopoietic stem cells encoding proinsulin transgenically targeted to 
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antigen-presenting cells completely prevents the development of spontaneous autoimmune 
diabetes in NOD mice (Steptoe et al., 2003). Transplantation of BM genetically engineered to 
express myelin oligodendrocyte glycoprotein (MOG) led to the deletion of MOG-specific 
thymocytes and prevented the induction and progression of EAE (Chan et al., 2008).  
Transplantation of genetically engineered autologous BM cells expressing diabetes-resistant 
MHC class II molecules (I-Ab) into NOD mice prevented the development of autoreactive T 
cells via negative selection and prevented the progression of diabetes (Tian et al., 2004).  
Genetic modification of stem cells or differentiated tissue cells with a decoy receptor for 
inflammatory cytokines can be used to treat autoimmune diseases. For example, NOD/SCID 
mice administered with MSCs genetically modified to secrete the soluble TNF receptor II 
exhibit decreased concentration of serum TNF-α.  
My previous study revealed that transplantation of adipose tissue-derived MSCs 
transduced with the CTLA4Ig gene by using a lentiviral vector reduces the inflammatory 
immune response and improves Th1/Th2 balance in experimental autoimmune thyroiditis 
(Choi EW et al., 2011). This study showed that MSCs can be efficiently transduced using 
lentiviral vectors to express therapeutic proteins and can retain their immunophenotype 
even after genetic manipulation. Moreover, the concentration of murine CTLA4Ig in the 
culture supernatants of CTLA4Ig-transduced MSCs was sustained at higher passages, 
indicating that MSCs genetically modified using the lentiviral system provide durable 
expression of therapeutic genes. Similarly, insertion of inducible regulatory genes into the 
stem cell compartment is expected to alter disease activity. Genetically modified stem cells 
that secrete immunomodulatory factors (e.g., IL-10, IDO, PGE2, TGF-β) and home to injured 
targets have great potential for treating various diseases, including autoimmune diseases.  
5. Conclusion 
During the past several decades, strategies using agents that influence cytokines, 
hyperactivity of B cells, and B cell-T cell interaction have been developed and some of these 
agents have proven to be effective and well tolerated therapies for autoimmune diseases. 
Although some of these treatments have yielded encouraging and promising results, 
prospective well-planned studies and international cooperation are required to collect 
experiences and clarify further details on safety and clinical efficacy depending on the 
disease states and the condition of patients.  
Hematopoietic stem cell therapy removes misguided inappropriate immune cells, restores 
immune cells, and resets or re-educates the immune system. Promising results have been 
reported from clinical trial studies. Some patients achieved durable remission, and transplant-
related mortality has decreased. MSCs are easily available, possess extensive capacity for in 
vitro expansion, and exhibit homing effects and immunomodulatory functions. Thus, MSCs 
have been targeted by researchers as an alternative source of treatment for autoimmune 
diseases. Stem cell therapy may be integrated with other therapeutic agents, including 
biologics and new intelligent molecules, for greater immunomodulation. 
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Stem cell-based gene therapy has great potential as a novel method for immunomodulation 
in autoimmune diseases. By identifying the correct gene for autoimmune disease treatment, 
stem cell-based gene therapy will be able to produce a synergic effect of gene therapy and 
stem cell therapy. Before they are put to clinical use, genetically engineered cells should be 
carefully tested at the genetic, molecular, and cellular levels.  
Selection and application of the appropriate therapy from among the various new 
therapeutic agents should be based on the risk-benefit analysis for each patient, because 
patients with autoimmune diseases exhibit different symptoms and severities and different 
responses to each treatment. Further studies are warranted to identify new specific targets 
and determine regimens to optimize the clinical response depending on the disease states. 
The development of non-toxic and effective novel gene transfer systems and clinical trials to 
evaluate combination therapies using agents that achieve immunomodulation or induce 
immune tolerance via different targets are also needed.  
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